LON:POLB Poolbeg Pharma (POLB) Share Price, News & Analysis → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free POLB Stock Alerts GBX 13.75 +0.15 (+1.10%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range 13.55▼ 13.9550-Day Range 8.85▼ 14.9052-Week Range 6.38▼ 15.77Volume2.02 million shsAverage Volume2.27 million shsMarket Capitalization£68.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesInsider TradesStock AnalysisChartCompetitorsHeadlinesInsider Trades Get Poolbeg Pharma alerts: Email Address Ad Crypto 101 MediaThe Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide About Poolbeg Pharma Stock (LON:POLB)Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass broad spectrum RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.Read More POLB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart POLB Stock News HeadlinesMay 1, 2024 | lse.co.ukPoolbeg Pharma celebrates full patent approval for Immunomodulator IIMay 1, 2024 | finance.yahoo.comPoolbeg Pharma and Silk Road Therapeutics announce strategic collaboration on novel orphan drugMay 12, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)May 1, 2024 | finance.yahoo.comPoolbeg Pharma PLC Announces Significant POLB 001 Patent Granted in USAApril 30, 2024 | finance.yahoo.comPoolbeg Pharma PLC Announces Results for the Year Ended 31 December 2023April 29, 2024 | finance.yahoo.comPoolbeg Pharma PLC Announces TR-1: Notification of Major HoldingsMarch 27, 2024 | finance.yahoo.comFavourable Signals For Poolbeg Pharma: Numerous Insiders Acquired StockMarch 20, 2024 | proactiveinvestors.comPoolbeg Pharma moves closer to locking down IP protection for key...May 12, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)February 22, 2024 | finance.yahoo.comPoolbeg Pharma PLC Announces Director/PDMR ShareholdingFebruary 20, 2024 | finance.yahoo.comPoolbeg Pharma chair discusses shift to executive role; hVIVO share saleFebruary 19, 2024 | finance.yahoo.comPoolbeg Pharma PLC Announces Director Share PurchaseFebruary 15, 2024 | finance.yahoo.comWe Think Poolbeg Pharma (LON:POLB) Can Afford To Drive Business GrowthFebruary 15, 2024 | msn.comPoolbeg Pharma announces board role change and launch of EIPFebruary 15, 2024 | finance.yahoo.comPoolbeg Pharma PLC Announces Board Role Change and Launch of EIPFebruary 12, 2024 | finance.yahoo.comPoolbeg Pharma says research confirms $10B plus opportunity for POLB 001 in cancer immunotherapiesFebruary 12, 2024 | finance.yahoo.comPoolbeg Pharma PLC Announces Market Opportunity for POLB 001 for CRSFebruary 8, 2024 | finance.yahoo.comPoolbeg Pharma's new VP of Clinical Operations Laura Maher aims to help progress development assetsJanuary 17, 2024 | finance.yahoo.comPoolbeg Pharma PLC Announces Further Data Shows POLB001 Potential in Cancer CRSDecember 20, 2023 | msn.comPoolbeg Pharma identifies promising RSV drug candidates as part of AI-led programmeDecember 20, 2023 | finance.yahoo.comPoolbeg Pharma PLC Announces RSV AI Drug Candidate Analysis UpdateDecember 11, 2023 | finance.yahoo.comPoolbeg Pharma PLC Announces POLB 001 Data Presented at ASHNovember 30, 2023 | proactiveinvestors.comPoolbeg Pharma non-exec steps down from boardNovember 30, 2023 | finance.yahoo.comPoolbeg Pharma PLC Announces Directorate ChangeNovember 21, 2023 | lse.co.ukTRADING UPDATES: Poolbeg hails approval; EDX links with Thermo FisherNovember 21, 2023 | proactiveinvestors.comPoolbeg Pharma lands Japanese patent grant for lead assetNovember 21, 2023 | finance.yahoo.comPoolbeg Pharma PLC Announces Immunomodulator II Patent Granted in JapanSee More Headlines Receive POLB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Poolbeg Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:POLB CUSIPN/A CIKN/A Webwww.poolbegpharma.com Phone44 20 7183 1499FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-3,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-24.00% Return on Assets-18.14% Debt Debt-to-Equity RatioN/A Current Ratio13.69 Quick Ratio47.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 6.53 per share Price / Cash Flow2.11 Book ValueGBX 3 per share Price / Book4.58Miscellaneous Outstanding Shares500,000,000Free FloatN/AMarket Cap£68.75 million OptionableNot Optionable Beta2.16 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Cathal Martin Friel (Age 60)Executive Chairman of The Board Comp: $138kDr. Jeremy Skillington Ph.D. (Age 53)CEO & Director Comp: $310kMr. Ian O'Connell (Age 37)CFO & Director Comp: $220kCarol DaltonVice President of Investor Relations & Public RelationsMr. John McEvoySenior Vice President & Chief Legal OfficerMr. David James Allmond (Age 54)Chief Business Officer Mr. Salim Gulamabbas Hamir F.C.A.Company SecretaryMr. Ross CrockettGroup Financial ControllerMore ExecutivesKey CompetitorsOpen OrphanLON:ORPHScancellLON:SCLPMereo BioPharma Group plc (MPH.L)LON:MPHRedx PharmaLON:REDXe-therapeuticsLON:ETXView All CompetitorsInsidersJeremy SkillingtonBought 154,764 shares on 2/21/2024Total: £1.70 M ($11.00/share)Cathal FrielBought 830,000 shares on 2/19/2024Total: £9.96 M ($12.00/share)View All Insider Transactions POLB Stock Analysis - Frequently Asked Questions How have POLB shares performed in 2024? Poolbeg Pharma's stock was trading at GBX 9.05 at the start of the year. Since then, POLB stock has increased by 51.9% and is now trading at GBX 13.75. View the best growth stocks for 2024 here. How do I buy shares of Poolbeg Pharma? Shares of POLB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:POLB) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward Press[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Poolbeg Pharma PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
